Exelixis Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.61 Intrinsic Value $75.91median of 6 methods · middle span $34-$262based on filings through 3 Jul 2026 Market Price $57.94Price as of 1 Oct 2026 UndervaluedIntrinsic value is 31% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $14.4B Shares Outstanding 259.1M diluted Moat Rating Wide Next Earnings Date3 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Exelixis combines a growing and profitable cabozantinib franchise with a potentially transformative but binary near-term regulatory catalyst for zanzalintinib. Second-quarter 2026 U.S. cabozantinib-franchise net product revenue reached $573.0 million, while management maintained substantial full-year revenue expectations after narrowing them. Zanzalintinib's NDA is under FDA review with a December 3, 2026 action date, supported by statistically significant overall-survival improvement in the STELLAR-303 intention-to-treat population. However, the non-liver-metastases subgroup did not achieve statistical significance, and STELLAR-304 remains an important unreported phase 3 test. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$41.00 Mean target$52.94 High · most bullish analyst$66.00 Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $41.0023% The FDA delays or rejects the zanzalintinib application, imposes a commercially restrictive label, or STELLAR-304 misses at least one primary endpoint. Concurrently, cabozantinib net product revenue falls below the revised guidance floor, increasing dependence on an aging flagship franchise and reducing confidence in the timing of a second growth platform. Base CaseCentral scenario $52.9457% Matches the consensus meanCABOMETYX continues to generate substantial revenue within the revised 2026 guidance range while investors await the December 2026 FDA decision and second-half STELLAR-304 data. Zanzalintinib retains meaningful strategic value, but the missed statistical threshold in the STELLAR-303 non-liver-metastases subgroup and normal regulatory uncertainty constrain conviction. Bull CaseUpside scenario $66.0020% The FDA approves zanzalintinib plus atezolizumab by the assigned action date without a materially restrictive label, establishing Exelixis's second commercial franchise. CABOMETYX remains within or above revised 2026 guidance, and STELLAR-304 reports favorable primary-endpoint results, supporting expansion of zanzalintinib beyond colorectal cancer. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |